As the waiting time for heart transplantation continues to increase due to shortage in organ donation, supporting patients with advanced heart failure with left ventricular assist device (LVAD) increases as well. The latest generation of LVAD, left ventricular assist system (LVAS) started to expand worldwide due to more promising outcomes. The aim of this article was to present the case of treating advanced heart failure in a patient who underwent implantation of HeartMate 3 LVAS as the bridge to transplantation. Case otline The patient was a 59-year-old man with advanced heart failure requiring inotropic drug support, with ischemic cardiomyopathy as the underlying cause of heart failure. Therefore, in the absence of an adequate donor, it was decided to incorporate the LVAS as a bridge to transplantation. Functional capacity, cardiac, renal, and liver functions improved in the patient. Conclusion The use of the HeartMate 3 in an advanced heart failure patient results in improvements in functional capacity, cardiac, renal and liver function. Further studies should be performed in order to identify whether improved outcomes are sustained with a longer follow-up period.
INTRODUCTION
Patients with advanced heart failure (HF) have quite limited possibilities for therapy, so the morbidity and mortality in connection to the disease are unacceptably high. In light of the insufficient availability of donor hearts and a growing number of heart transplantation (HT) ineligible patients, left ventricular assist devices (LVAD) are often used to support patients with advanced HF awaiting HT or as destination therapy (DT) [1] . In order to improve clinical outcomes of LVAD therapy, technological advances have been made through different types of LVAD pumps over the past 30 years, from pulsatile to continuous flow (CF) and now back to artificial pulsatility. Compared to the pulsatile flow HeartMate (HM) XVE, the newer generation of LVAD and CF-LVAD is considerably smaller, with significantly lower incidence of adverse events and has become the standard of care as a bridge to transplantation (BTT) [1] . HM II (Abbott Corporation, Chicago, IL, USA) is an axial pump that provides CF, which requires a tissue pocket and a larger body surface of the patient, while other intrapericardial CF pumps, like HeartWare (HeartWare Inc., Framingham, MA, USA), utilize a magnetically levitating rotor system to decrease mechanical wear in order to reduce hemolysis and the incidence of pump thrombosis. Also, due to smaller size, it is suitable for patients with smaller body surface area [2] . Despite the fact that with the newer generation of LVAD survival rate is much better, the overall adverse events are still significantly high [3] . Therefore, technology enhancements of LVAD have become increasingly important in order to improve post-LVAD outcomes and to reduce the rate of adverse events. The latest generation pump, HM 3 (Abbott Corporation) is intrapericardial fully magnetically levitated CF-LVAD with artificial pulsatility with large, consistent pump gaps designed to reduce blood trauma and minimize stasis of blood.
The aim of this article was to present a case of treating the end-stage of HF in a patient in whom the latest generation of LVAD, left ventricular assist system (LVAS), HM 3, was implanted.
CASE REPORT
The patient was a 59-year-old man with advanced HF, with ischemic cardiomyopathy as the underlying cause. Ten months prior to hospitalization at our institution, the patient suffered from acute heart infarction of the anterior wall as the first manifestation of coronary disease. Since the patient was admitted to a local hospital after 24 hours had passed, neither percutaneous coronary intervention nor fibrinolysis was applied. At the local hospital, the patient underwent coronary angiography that showed an occlusion of the left anterior descending coronary artery and stenosis of the proximal circumflex coronary artery and he was treated with medicaments. After the acute ischemic phase, the hospital treatment was hindered by the development of left ventricular (LV) aneurysm and the appearing symptoms of HF. He complained of fatigue while at rest, of choking, chest pain, and swelling in the legs. Ten months after the myocardial infarction, he came to our institution due to symptoms of advanced HF and required inotrope support drugs. Both two-dimensional transthoracic echocardiography (TTE) and transesophageal echocardiography (TEE) were performed in the standard manner using Vivid E 9 (GE Medical Systems, Milwaukee, WI, USA) and showed a volume overload of LV (EDV 257 ml), increased LV end-diastolic (LVEDD) and end-systolic diameters (LVESD), 7.4 cm and 6.3 cm, respectively, and significantly decreased ejection fraction of LV (LVEF) to 18% calculated by the Biplane method. There were akinesis in the LV septum, apex, apical part of anterolateral and inferior walls, apical and medial part of the anterior wall with LV apex aneurysm without visible thrombotic masses. Severe mitral regurgitation (MR 3+) was present. The right ventricle had regular dimensions (2.6 cm) with good systolic and longitudinal functions (global fractional area change of 27%, tricuspid annular plane systolic excursion of 21 mm, and right ventricular systolic excursion velocity of 18 cm/s). There was severe functional tricuspid regurgitation (TR 3+) with high right ventricle systolic pressure (RVSP 77 mmHg). Single-photon emission computed tomography showed the absence of viable myocardium of the septum, anterior and lateral wall of the LV. Preoperative hemodynamic data showed pulmonary capillary wedge pressure (PCWP) of 27 mmHg, central venous pressure (CVP) of 11 mmHg, cardiac index (CI) of 1.9 L/min./m 2 . In order to assess the possibility of LVAS implantation, the nature of the LV apex aneurysm was estimated by performing magnetic resonance imaging of the heart. At the part of LV apex aneurysm, the myocardial wall thickness was 3-5 mm with aneurysmal extension, which was a borderline finding for pump implantation. Based on all the performed tests, it was concluded that the patient was in the end-stage of HF (New York Heart Association (NYHA) IV, Interagency Registry for Mechanically Assisted Circulatory Support 3), with significantly impaired LV function requiring continuous inotropic support; therefore, it was decided in the absence of an adequate donor to incorporate the LVAS as a BTT.
The patient underwent surgery under general anesthesia. The surgery included the implantation of LVAS, HM 3. After median sternotomy, in conditions of extracorporeal circulation without aortic clamping and stopping of the heart, the LV was opened at the top, the ring was sewn, and after preparation, the pump was connected to the ring. The driveline was placed through the skin in the form of double tunneling and connected to the pump controller and the energy source. Finally, a graft was sewn to the aorta ( Figure  1 ). Unlike the LVAD HM 2 device, where it is necessary to form a tissue pocket to place the device, LVAS HM 3 was applied fully intrapericardially. The intervention was without complications.
The postoperative recovery was uneventful. After the LVAS implantation, a standardized anticoagulation regimen was used with initiation of infusion of heparin, followed by the transition to warfarin and aspirin. Anticoagulation therapy was included in order to maintain the international normalized ratio between 2.0 and 3.0. There was normal flow through both the pump's inflow and outflow cannula. The pump speed was set at 4,900 rpm, with pump flow being 3.4 L/min. and pump power 3.2 w. There were stable LVAS parameters and data on the pump controller. The radiographic finding was regular (Figure 2 ). Postoperative hemodynamic data showed PCWP of 10 mmHg, CVP of 7 mmHg, CI of 3.2 L/min./m 2 . Functional cardiac (TTE and brain-type natriuretic peptide -BNP), renal and liver function assessments were done before the LVAD implantation, at discharge from the hospital and at 12 months. The TTE examination at discharge showed improvement in the LVEDD and the LVESD from baseline values of 7.4 and 6.3 to 5.5 and 4.5, respectively. This improvement was sustained over the time of the follow-up. For LVEF and BNP (pg/ml), the baseline values of 18% and 670 improved to 39% and 173, respectively, and continued to improve during the period of 12 months to 50% and 120, respectively. The dimension of the right ventricle was sustained in the normal range (2.6 cm) with a good systolic function. At discharge, NYHA functional classification improved from IV at baseline to II and continued to improve to I during the period of 12 months. There were improvements in renal function from baseline-estimated glomerular filtration rate (ml/min./1.73 m 2 ) and serum creatinine (nmol/L) of 40 and 155 to 57 and 114, respectively, and there was no change over the entire follow-up period. With regard to hepatic function, total bilirubin (μmol/L) showed a reduction at the discharge point (25.8 vs. 12.4), with no further change afterwards. There were no significant changes of aspartate transaminase (IU/L), and alanine transaminase (IU/L) values during the entire follow-up period.
DISCUSSION
HT remains the treatment of choice in cardiac replacement therapy for patients with end-stage HF. As the waiting time for HT continues to increase, supporting patients with LVAD increases as well. LVAD support enables an improved quality of life and survival compared to medical therapy [4] . However, despite all of these benefits of new technology of LVAD, there is still significant incidence of devicerelated complications that may have lessened enthusiasm for investigating LVAD therapy in less sick patients [5] .
LVAD technology is advancing continuously and rapidly. Smaller devices, total implantability, artificial pulsatility, and remote monitoring are being investigated, which will broaden the LVAD technology application. The outcomes in patients supported by the LVAD have improved along with experience and technology advances. The HM 3 LVAS is a new centrifugal-flow device which uses full magnetic levitation allowing wide and consistent flow paths and an artificial pulse designed for enhanced hemocompatibility. It uses a fully magnetically levitated rotor with frictionless movement that excludes heat generation and wear of the moving component. During operation, blood from the LV enters the inflow cannula and pump along a central axis and is propelled through the wide-gap impeller blades of the rotor and finally out through the outflow graft. The power cable from the pump housing is externalized and connected to a modular cable that is attached to the external system controller and a power supply. The pump receives power from a power module or mobile power unit for wall power, or from a pair of 14-V lithium-ion batteries. The pump operates at a rotor speed in the range of 3,000-9,000 rpm and the maximum flow rate is 10 L/min. The LVAS operates continuously in an artificial pulse mode, where the rotor speed changes rapidly every 2 seconds to generate pulsatile flow from the pump [6] .
The use of a HM 3 in advanced HF patients results in improvements in functional capacity, cardiac, renal, and liver function. LVAD technology is quickly evolving and its accessibility is increasing if compared to HT. Further studies should be performed in order to identify whether improved outcomes are sustained with a longer follow-up period.
